Slide 1: Conference Call Q1 2021 Results
Conference Call Q1 2021 Results Joachim Kreuzburg, Rainer Lehmann Sartorius | Sartorius Stedim Biotech April 21, 2021
Slide 2: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha
Slide 3: Highlights Q1 2021
Highlights Q1 2021 Both divisions with 60+ percent top-line growth and substantial margin expansion Strong organic growth plus significant impact from corona related businesses and acquisitions Q1 top-line and bottom-line growth impacted by low comparative base and temporary effects Accelera
Slide 4: Agenda
Agenda Sartorius Group Q1 2021 results | FY 2021 guidance Sartorius Stedim Biotech Group Q1 2021 results | FY 2021 guidance Questions & Answers 4
Slide 5: Strong profitable growth
Strong profitable growth Sartorius Group Q1 2020 Q1 2021 in % in % cc1 in millions of € unless otherwise specified Sales revenue 509.9 791.1 +55.1 +61.6 Order intake 629.4 1,138.6 +80.9 +89.2 Underlying EBITDA2 137.9 263.5 +91.2 Underlying EBITDA2 margin in % 27.0 33.3 +6.3pp Underlying EPS3 (ord.)
Slide 6: High double-digit sales growth in all geographies
High double-digit sales growth in all geographies Americas EMEA Asia|Pacific Sales by Region € in millions € in millions € in millions in % +53.4% +63.1% +71.1% EMEA 334.4 ~ 42% Americas 253.1 ~ 32% 207.0 203.6 180.7 122.2 €791.1m Asia|Pacific Q1 2020 Q1 2021 Q1 2020 Q1 2021 Q1 2020 Q1 2021 ~ 26%
Slide 7: BPS: Dynamic growth across all product categories and regions
BPS: Dynamic growth across all product categories and regions Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +97.1% cc +61.4% cc +81.1% +88.3% +54.9% 953.0 217.1 610.7 506.2 119.9 394.3 35.6% 30.4% Q1 2020 Q1 2021 Q1 2020 Q1 2021 Q1 2020 Q1 2021 Str
Slide 8: LPS: Strong performance against weaker prior-year comps
LPS: Strong performance against weaker prior-year comps Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +56.8% cc +62.3% cc +157.9% +50.5% +56.0% 185.6 180.3 46.4 123.3 115.6 18.0 25.7% 15.6% Q1 2020 Q1 2021 Q1 2020 Q1 2021 Q1 2020 Q1 2021 Significan
Slide 9: Operating cash flow increases significantly
Operating cash flow increases significantly Sartorius Group Net operating cash flow mostly driven by higher Q1 2020 Q1 2021 in % earnings in millions of € unless otherwise specified Underlying EBITDA 137.9 263.5 +91.2 Extraordinary items in prior-year influenced by M&A and corporate projects Ext
Slide 10: Financial indicators remain on very solid level
Financial indicators remain on very solid level Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Dec. 31, Mar. 31, Sartorius Group 2,000 4.0 2020 2021 1,500 3.0 Equity ratio in % 29.9 29.7 1,000 2.0 Net debt in millions of € 1,883.6 1,822.7 500 1.0 0 0.0 Net debt | underlying 2.6
Slide 11: Outlook for 2021 confirmed, uncertainties remain higher than usual
Outlook for 2021 confirmed, uncertainties remain higher than usual FY 2021 Guidance1 Sales revenue growth Underlying EBITDA margin Sartorius Group ~35% ~32% growth by acquisitions | Corona demand ~5.5pp | ~16pp Bioprocess Solutions ~40% ~34% growth by acquisitions | Corona demand ~6pp | ~18pp Lab Pr
Slide 12: Agenda
Agenda Sartorius Group Q1 2021 results | FY 2021 guidance Sartorius Stedim Biotech Group Q1 2021 results | FY 2021 guidance Questions & Answers 12
Slide 13: Exceptionally strong and profitable growth in Q1 2021
Sartorius Stedim Biotech Group Exceptionally strong and profitable growth in Q1 2021 Sartorius Stedim Biotech Group Q1 2020 Q1 2021 in % in % cc1 in millions of € unless otherwise specified Sales revenue 422.1 655.2 +55.2 +61.1 Order intake 534.8 1,004.4 +87.8 +95.9 Underlying EBITDA2 126.7 231.6 +8
Slide 14: High double-digit sales growth in all geographies
Sartorius Stedim Biotech Group High double-digit sales growth in all geographies Americas EMEA Asia|Pacific Sales by Region € in millions € in millions € in millions in % +45.2% +70.8% +68.5% EMEA 284.1 ~ 43% Americas ~ 31% 204.0 152.7 167.6 167.1 €655.2m 101.7 Asia|Pacific ~ 26% Q1 2020 Q1 2021 Q1
Slide 15: Operating cash flow rises significantly
Sartorius Stedim Biotech Group Operating cash flow rises significantly Sartorius Stedim Biotech Group Net operating cash flow mostly driven by higher Q1 2020 Q1 2021 in % earnings in millions of € unless otherwise specified Underlying EBITDA 126.7 231.6 +82.8 Extraordinary items in prior-year in
Slide 16: Financial indicators remain on very solid level
Sartorius Stedim Biotech Group Financial indicators remain on very solid level Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA 600 1.8 Dec. 31, Mar. 31, Sartorius Stedim Biotech 2020 2021 500 1.5 400 1.2 Equity ratio in % 48.3 47.0 300 0.9 200 0.6 Net debt in millions of € 527.0
Slide 17: Outlook for 2021 confirmed, uncertainties remain higher than usual
Sartorius Stedim Biotech Group Outlook for 2021 confirmed, uncertainties remain higher than usual Sales growth1 Underlying EBITDA margin1 Sartorius Stedim Biotech ~38% ~33% Of which acquisitions | Corona demand ~5.5pp | ~18pp CAPEX ratio ~14% (FY 2020: 8.3%); increase due to acceleration and exten
Slide 18: Questions & Answers
Questions & Answers 18